Amplifold GmbH

Founded in 2025 in Bavaria, Germany, Amplifold is a biotechnology spin‑off from Ludwig‑Maximilians‑Universität München. co-founded by Enzo Kopperger, Federico Bürsgens, Gabriela Franco, Heini Ijäs, Julian Trommler, Maximilian Urban, and Tim Liedl. The company uses DNA‑origami technology to improve the sensitivity of lateral‑flow diagnostic tests. In November 2025, Amplifold GmbH raised seed funding from Matterwave Ventures Management Bayern Kapital, b2venture, Becker Ventures and XISTA Science Ventures.

The seed round of funding values EUR 19. 06 million post-money. Amplifold provides a DNA‑origami–based module that can be used with standard lateral‑flow tests. The technology increases test sensitivity without changing existing manufacturing steps.

It can be applied in areas such as infectious disease testing, cardiovascular and neurological diagnostics, and point‑of‑care use. The company works with diagnostic makers to integrate its module into common rapid testing systems. Amplifold earns revenue through partnerships and licensing arrangements with diagnostic manufacturers. Its approach allows these companies to use the amplification module within their current lateral‑flow test production processes without requiring major changes to their setup.

The company plans to use its proceeds from November 2025 funding to to expand by hiring regulatory and engineering staff, working toward IVDR certification, and increasing production capacity. The company will move to the IZB biotech hub in Martinsried and continue developing its diagnostic improvement platform for practical use.